Benchmark、HC Wainwright 和 JMP Securities 维持或上调 Halozyme Therapeutics 的评级。 Benchmark, HC Wainwright, and JMP Securities maintain or upgrade Halozyme Therapeutics' ratings.
据 Benzinga 报道，Benchmark 重申对 Halozyme Therapeutics (HALO) 的买入评级，目标价为 50 美元。 Benchmark has reaffirmed its Buy rating for Halozyme Therapeutics (HALO) with a $50 price target, as reported by Benzinga. HC Wainwright 还将目标价从 48 美元上调至 50 美元，并给予买入评级，而 JMP Securities 维持市场优于大盘评级，目标价为 72 美元。 HC Wainwright also upgraded the target price from $48 to $50 and assigned a Buy rating, while JMP Securities maintained a Market Outperform rating with a $72 price target. 不过，TheStreet 将 Halozyme Therapeutics 的评级从 B- 下调至 C+，高盛也下调了其目标价。 However, TheStreet downgraded Halozyme Therapeutics from a B- to a C+ rating and Goldman Sachs lowered its target price.